LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of “Moderate Buy” by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $68.20.

A number of brokerages have weighed in on LMAT. KeyCorp assumed coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating for the company. Barrington Research boosted their price target on LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Finally, StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday.

LeMaitre Vascular Stock Down 0.5 %

LMAT opened at $64.12 on Wednesday. The business has a fifty day moving average of $64.88 and a 200 day moving average of $57.65. LeMaitre Vascular has a 52-week low of $44.27 and a 52-week high of $74.64. The stock has a market cap of $1.43 billion, a P/E ratio of 47.85, a PEG ratio of 2.79 and a beta of 0.87.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The company had revenue of $48.90 million during the quarter, compared to analysts’ expectations of $49.01 million. During the same quarter in the previous year, the business earned $0.25 EPS. LeMaitre Vascular’s revenue was up 19.3% compared to the same quarter last year. Equities analysts anticipate that LeMaitre Vascular will post 1.66 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, March 14th were issued a $0.16 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. The ex-dividend date of this dividend was Wednesday, March 13th. This represents a $0.64 dividend on an annualized basis and a yield of 1.00%. LeMaitre Vascular’s dividend payout ratio is presently 47.76%.

Insider Buying and Selling

In related news, Director John A. Roush sold 7,500 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $157,182. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares of the company’s stock, valued at $358,357.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John A. Roush sold 7,500 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $157,182. The disclosure for this sale can be found here. In the last 90 days, insiders sold 114,036 shares of company stock valued at $7,873,749. 12.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds have recently made changes to their positions in the company. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of LeMaitre Vascular in the fourth quarter valued at approximately $8,837,000. Congress Asset Management Co. MA increased its holdings in shares of LeMaitre Vascular by 36.3% in the third quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock valued at $27,696,000 after purchasing an additional 135,266 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of LeMaitre Vascular by 10.1% in the first quarter. Vanguard Group Inc. now owns 1,426,235 shares of the medical instruments supplier’s stock valued at $66,278,000 after purchasing an additional 130,881 shares during the last quarter. Ranger Investment Management L.P. increased its holdings in shares of LeMaitre Vascular by 15.8% in the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock valued at $48,968,000 after purchasing an additional 122,601 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in LeMaitre Vascular in the second quarter worth approximately $4,254,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.